us en false false Default
Skip directly to Accessibility Notice
PPH VanEck Pharmaceutical ETF Please read important disclosure Close important disclosure false

PPH
VanEck Pharmaceutical ETF

PPH
VanEck Pharmaceutical ETF

  • NAV
    $105.68

    as of May 28, 2026
  • YTD RETURNS
    3.33%

    as of May 28, 2026
  • Total Net Assets
    $960.44M

    as of May 28, 2026
  • Total Expense Ratio
    0.36%
  • Inception Date
    12/20/2011
Buy Now
Let's Connect
Subscribe
Related Insights

Overview

Why PPH

  • Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
  • Industry LeadersFavors established industry leaders with meaningful scale
  • Global ScopeProvides exposure to U.S. and international equities for global industry representation

VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

Performance

Average Annual Total Returns* (%)

View All ETFs View All Indices
  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE 12/20/11
PPH (NAV) -1.47 -3.81 -0.41 16.31 11.12 10.03 7.78 9.72
PPH (Market Price) -1.15 -3.86 -0.47 16.41 11.12 10.04 7.77 9.80
MVIS US Listed Pharmaceutical 25 Index -1.47 -3.93 -0.54 16.00 10.67 9.64 7.54 9.53
  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE 12/20/11
PPH (NAV) -6.68 1.08 1.08 16.72 12.58 10.67 8.18 9.90
PPH (Market Price) -7.00 0.69 0.69 16.33 12.45 10.57 8.14 9.95
MVIS US Listed Pharmaceutical 25 Index -6.77 0.94 0.94 16.36 12.11 10.28 7.94 9.70

*Returns less than one year are not annualized.

The performance data quoted represents past performance. Past performance is not a guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Performance may be lower or higher than performance data quoted. Please call 800.826.2333 or visit vaneck.com for performance current to the most recent month ended.

Holdings

Daily Holdings (%) as of 05/28/2026

Download XLS Get holdings
Total Holdings: 26
Ticker
 Holding Name
% of Net Assets
Market Value (US$)
LLY
 Eli Lilly & Co
22.57
214,393,982
NVS
 Novartis Ag
10.51
99,874,946
MRK
 Merck & Co Inc
9.51
90,335,197
NVO
 Novo Nordisk A/S
5.87
55,741,376
PFE
 Pfizer Inc
4.79
45,538,782
SNY
 Sanofi Sa/France
4.28
40,676,467
BMY
 Bristol-Myers Squibb Co
4.28
40,635,390
GSK
 Gsk Plc
4.19
39,789,448
ABBV
 Abbvie Inc
4.08
38,751,074
AZN
 Astrazeneca Plc
4.07
38,689,305
JNJ
 Johnson & Johnson
4.04
38,351,344
MCK
 Mckesson Corp
3.65
34,697,692
TEVA
 Teva Pharmaceutical Industries Ltd
3.20
30,353,401
COR
 Cencora Inc
3.14
29,799,336
HLN
 Haleon Plc
2.92
27,712,024
TAK
 Takeda Pharmaceutical Co Ltd
2.70
25,685,428
ZTS
 Zoetis Inc
2.27
21,531,451
VTRS
 Viatris Inc
1.06
10,024,174
JAZZ
 Jazz Pharmaceuticals Plc
0.98
9,327,874
AXSM
 Axsome Therapeutics Inc
0.70
6,625,876
CORT
 Corcept Therapeutics Inc
0.37
3,526,288
ELAN
 Elanco Animal Health Inc
0.35
3,316,218
OGN
 Organon & Co
0.22
2,043,752
BHC
 Bausch Health Cos Inc
0.10
972,756
PRGO
 Perrigo Co Plc
0.07
683,060
-USD CASH-
 --
-0.00
-27,431
--
Other/Cash
0.09
821,346
← Scroll for more information →
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Portfolio

Sector Weightings (%) as at 04/30/2026

  • Sector

    % of Net Assets

Country Weightings (%) as at 04/30/2026

  • Country

    % of Net Assets

  • United States

    61.12

  • United Kingdom

    11.71

  • Switzerland

    10.65

  • Denmark

    5.62

  • France

    4.65

  • Israel

    3.35

  • Japan

    2.88

  • Other/Cash

    0.01

Fees

Distributions

  as of  05/28/2026

Distribution Frequency

Quarterly

30-Day SEC Yield

1.96%

Distribution Yield

3.19%

12 Month Yield

2.04%

Yield information reflects temporary waivers of expenses and/or fees. Yields would have been reduced had these fees/expenses been included. In the absence of temporary expense waivers or reimbursements, the 30-Day SEC Yield for VanEck Pharmaceutical ETF would have been 1.96% on 05/28/26. Distributions may vary from time to time.

Team

Resources

Regulatory Information

Fund Documents

Thought Leadership

PPH